Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum.

17 December, 2024

Plasma p-tau217 in Alzheimer’s disease: Lumipulse and ALZpath SIMOA head-to-head comparison.

16 December, 2024

Plasma neurofilament light outperforms glial fibrillary acidic protein in differentiating behavioural variant frontotemporal dementia from primary psychiatric disorders.

15 December, 2024

Balance and gait disorders in de novo Parkinson’s disease: support for early rehabilitation.

12 December, 2024

Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort.

Multiomics profiling of DNA methylation, microRNA, and mRNA in skeletal muscle from monozygotic twin pairs discordant for type 2 diabetes identifies dysregulated genes controlling metabolism.

2 December, 2024

Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders.

19 November, 2024

Free Recall Outperforms Story Recall in Associations with Plasma Biomarkers in Preclinical Alzheimer Disease.

15 November, 2024

GBA1 T369M and Parkinson’s disease – Further evidence of a lack of association in the Swedish population.

31 October, 2024

A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests.

28 October, 2024

Individualized, cross-validated prediction of future dementia using cognitive assessments in people with mild cognitive symptoms.

25 October, 2024

Phosphorylated tau in cerebrospinal fluid-derived extracellular vesicles in Alzheimer’s disease: a pilot study

Biological mechanisms of resilience to tau pathology in Alzheimer’s disease.

12 October, 2024

Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer’s disease.

11 October, 2024

Considerations for widespread implementation of blood-based biomarkers of Alzheimer’s disease.

6 October, 2024

Recommendations for clinical implementation of blood-based biomarkers for Alzheimer’s disease.

1 October, 2024

Dementia in Down syndrome

30 September, 2024

Cerebrovascular disease is associated with Alzheimer’s plasma biomarker concentrations in adults with Down syndrome.

25 September, 2024

A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer’s Disease.

Association of in vivo retention of [18f] flortaucipir pet with tau neuropathology in corresponding brain regions.

19 September, 2024

Integrating amyloid and tau imaging with proteomics and genomics in Alzheimer’s disease

17 September, 2024

Medial temporal lobe atrophy patterns in early-versus late-onset amnestic Alzheimer’s disease.

16 September, 2024

Lewy body pathology exacerbates brain hypometabolism and cognitive decline in Alzheimer’s disease.

14 September, 2024

Associations between misfolded alpha-synuclein aggregates and Alzheimer’s disease pathology in vivo.

11 September, 2024

Proteomic changes in Alzheimer’s disease associated with progressive Aβ plaque and tau tangle pathologies.

26 August, 2024

The Alzheimer’s Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study.

22 August, 2024

Disentangling genetic risks for development and progression of Alzheimer’s disease.

1 August, 2024

The CentiMarker Project: Standardizing Quantitative Alzheimer’s disease Fluid Biomarkers for Biologic Interpretation

29 July, 2024

Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment

28 July, 2024

MRI Signature of α-Synuclein Pathology in Asymptomatic Stages and a Memory Clinic Population

Harmonizing tau positron emission tomography in Alzheimer’s disease: The CenTauR scale and the joint propagation model

23 July, 2024

A clinical perspective on the revised criteria for diagnosis and staging of Alzheimer’s disease

20 July, 2024

Clinical recognition of frontotemporal dementia with right anterior temporal predominance: A multicenter retrospective cohort study

10 July, 2024

Divergent functional connectivity changes associated with white matter hyperintensities

Continuous β-Amyloid CSF/PET Imbalance Model to Capture Alzheimer Disease Heterogeneity

9 July, 2024

Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease

6 July, 2024

A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings

5 July, 2024

A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker Tests

Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns

Acceptable performance of blood biomarker tests of amyloid pathology – recommendations from the Global CEO Initiative on Alzheimer’s Disease

1 July, 2024

Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup

27 June, 2024

Associations of modifiable and non-modifiable risk factors with cognitive functions – a prospective, population-based, 17 years follow-up study of 3,229 individuals

26 June, 2024

Effects of time of the day at sampling on CSF and plasma levels of Alzheimer’ disease biomarkers

22 June, 2024

In vivo detection of Alzheimer’s and Lewy body disease concurrence: Clinical implications and future perspectives

21 June, 2024

Structural and functional connectivity associations with anterior cingulate sulcal variability

20 June, 2024

Head-to-Head Comparison of Tau and Amyloid Positron Emission Tomography Visual Reads for Differential Diagnosis of Neurodegenerative Disorders: An International, Multicenter Study

18 June, 2024

MRI-Derived AD Signature of Cortical Thinning and Plasma P-Tau217 for Predicting Alzheimer Dementia Among Community-Dwelling Older Adults

15 June, 2024

Prediction of future cognitive decline among cognitively unimpaired individuals using measures of soluble phosphorylated tau or tau tangle pathology

13 June, 2024

Remote and unsupervised digital memory assessments can reliably detect cognitive impairment in Alzheimer’s disease

12 June, 2024

Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment

10 June, 2024

Identification of distinct and shared biomarker panels in different manifestations of cerebral small vessel disease through proteomic profiling

A machine learning-based prediction of tau load and distribution in Alzheimer’s disease using plasma, MRI and clinical variables

31 May, 2024

Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly

23 May, 2024

Medial temporal lobe atrophy patterns in early- versus late-onset amnestic Alzheimer’s disease

21 May, 2024

Plasma p-tau217 in Alzheimer’s disease: Lumipulse and ALZpath SIMOA head-to-head comparison

3 May, 2024

Fixel-Based Analysis Reveals Tau-Related White Matter Changes in Early Stages of Alzheimer’s Disease

1 May, 2024

Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases

Biomarker-based staging of Alzheimer disease: rationale and clinical applications

20 April, 2024

Plasma glial fibrillary acidic protein and tau: predictors of neurological outcome after cardiac arrest

9 April, 2024

Associations between structural brain changes and blood neurofilament light chain protein in treatment-resistant schizophrenia

8 April, 2024

Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration.

28 March, 2024

Altered empathy processing in frontotemporal dementia A task-based fMRI study

26 March, 2024

Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms

19 March, 2024

Is GBA1 T369M not a risk factor for Parkinson’s disease in the Swedish population?

16 March, 2024

A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings

14 March, 2024

Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer’s disease.

1 March, 2024

Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulation.

Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease.

17 February, 2024

Prognostic and Predictive Factors in Early Alzheimer’s Disease: A Systematic Review.

16 February, 2024

Putaminal T1/T2-weighted ratio is increased in PSP compared to PD and healthy controls, a multi-cohort study.

13 February, 2024

The Relationship between p-tau217, p-tau231, and p-tau205 in the Human Brain Is Affected by the Cellular Environment and Alzheimer’s Disease Pathology.

11 February, 2024

Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.

Effects of certain pre-analytical factors on the performance of plasma phospho-tau217.

8 February, 2024

Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease.

Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases.

7 February, 2024

Diffusion weighted magnetic resonance spectroscopy revealed neuronal specific microstructural alterations in Alzheimer’s disease.

1 February, 2024

Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology.

7 January, 2024

The fluorescent ligand bTVBT2 reveals increased p-tau uptake by retinal microglia in Alzheimer’s disease patients and App^NL-F/NL-F mice.

2 January, 2024

Harnessing cognitive trajectory clusterings to examine subclinical decline risk factors.

3 December, 2023

The molecular genetic landscape of human brain size variation.

28 November, 2023

Effects of Brain Pathologies on Spatiotemporal Gait Parameters in Patients with Mild Cognitive Impairment.

31 October, 2023

Cognitive effects of Lewy body pathology in clinically unimpaired individuals.

14 September, 2023

Clinical effects of Lewy body pathology in cognitively impaired individuals.

CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease.

Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring.

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology.

11 September, 2023

Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes.

Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.

Higher plasma β-synuclein indicates early synaptic degeneration in Alzheimer’s disease.

Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms.

Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders.

Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets.

Direct Conversion of Fibroblast into Neurons for Alzheimer’s Disease Research: A Systematic Review

25 August, 2023

Blood biomarkers for Alzheimer’s disease in clinical practice and trials.

11 August, 2023

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease.

12 June, 2023

Age-related and amyloid-beta-independent tau deposition and its downstream effects.

Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App^NL-F/NL-F knock-in mouse model of Alzheimer’s disease.

Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease.

Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia.

Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.

Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer’s disease.

Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes.

Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi-cohort study.

Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients.

Novel insights regarding the measurement properties of the SCOPA-AUT.

[¹⁸F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes.

Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum.

The genetic regulation of protein expression in cerebrospinal fluid.

Cerebrospinal Fluid Biomarkers of Synaptic Dysfunction are Altered in Parkinson’s Disease and Related Disorders.

Performance of [¹⁸F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy.

Gray matter hypoperfusion is a late pathological event in the course of Alzheimer’s disease.

CSF ferritin in the clinicopathological progression of Alzheimer’s disease and associations with APOE and inflammation biomarkers.

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease.

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease.

Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy.

Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease.

Confounding factors of Alzheimer’s disease plasma biomarkers and their impact on clinical performance.

Clinical performance and robustness evaluation of plasma amyloid-β_42/40prescreening.

Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease.

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease.

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.

Anterior cingulate sulcation is associated with onset and survival in frontotemporal dementia.

Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios.

The emerging era of staging Alzheimer’s disease pathology using plasma biomarkers

2 May, 2023

Plasma neurofilament light is a predictor of neurological outcome 12 h after cardiac arrest

24 February, 2023

Spatial Navigation and Its Association With Biomarkers and Future Dementia in Memory Clinic Patients Without Dementia.

17 June, 2022

Earlier Alzheimer’s disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading.

An accurate fully automated panel of plasma biomarkers for Alzheimer’s disease.

Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials.

Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease.

Astrocytic function is associated with both amyloid-β and tau pathology in non-demented APOE ϵ4 carriers.

Test-retest variability of plasma biomarkers in Alzheimer’s disease and its effects on clinical prediction models.

β-Amyloid-Dependent and -Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease.

Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217.

Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients.

Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer’s Disease Pathology and Cognitive Decline.

Midsagittal corpus callosal thickness and cognitive impairment in Parkinson’s disease.

Subtypes of Alzheimer’s disease: questions, controversy, and meaning.

Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.

The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders.

Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer’s disease and frontotemporal disorders in clinical settings.

Components of gait in people with and without mild cognitive impairment.

Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.

Blood-based biomarkers for Alzheimer’s disease.

Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation.

Serum Neurofilament Light Chain as a Marker of Progression in Parkinson’s Disease: Long-Term Observation and Implications of Clinical Subtypes.

Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network.

Insights on Genetic and Environmental Factors in Parkinson’s Disease from a Regional Swedish Case-Control Cohort.

Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau.

Decreased pain sensitivity and alterations of cerebrospinal fluid and plasma inflammatory mediators after total hip arthroplasty in patients with disabling osteoarthritis.

The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.

Prenatal Gyrification Pattern Affects Age at Onset in Frontotemporal Dementia.

Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition.

Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels.

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias.

3 February, 2022

Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson’s disease.

30 June, 2021

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures

24 June, 2021

Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline.

14 June, 2021

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.

Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.

The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals.

Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease-related blood-based biomarkers: Results from the Standardization of Alzheimer’s Blood Biomarkers (SABB) working group.

Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network.

The global Alzheimer’s Association round robin study on plasma amyloid β methods.

Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease.

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum.

Inter-modality assessment of medial temporal lobe atrophy in a non-demented population: application of a visual rating scale template across radiologists with varying clinical experience.

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease.

Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers.

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.

Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau.

Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations.

A multicentre validation study of the diagnostic value of plasma neurofilament light.

Sex differences in off-target binding using tau positron emission tomography.

Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects.

The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.

A multicenter comparison of [¹⁸F]flortaucipir, [18F]RO948, and [¹⁸F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis.

Health utility in preclinical and prodromal Alzheimer’s disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study.

Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau.

Four distinct trajectories of tau deposition identified in Alzheimer’s disease.

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias.

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia.

Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid,
tau, and cognition.

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer’s
disease.

Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s
disease.

Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for
synaptic biomarkers.

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future
conversion to Alzheimer dementia in patients with mild cognitive impairment.

A multisite analysis of the concordance between visual image interpretation and
quantitative analysis of [¹⁸F]flutemetamol amyloid PET images.

Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s
disease.

Biomarker testing in MCI patients-deciding who to test.

Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts.

Early stages of tau pathology and its associations with functional connectivity, atrophy and memory.

30 April, 2021

Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease.

3 February, 2021

Pre-analytical protocol for measuring Alzheimer’s disease biomarkers in fresh CSF.

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies.